These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 2226221)

  • 1. Mexiletine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias.
    Monk JP; Brogden RN
    Drugs; 1990 Sep; 40(3):374-411. PubMed ID: 2226221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacology and clinical use of mexiletine.
    Fenster PE; Comess KA
    Pharmacotherapy; 1986; 6(1):1-9. PubMed ID: 3513138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mexiletine: pharmacology and therapeutic use.
    Manolis AS; Deering TF; Cameron J; Estes NA
    Clin Cardiol; 1990 May; 13(5):349-59. PubMed ID: 2189614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacology, electrophysiology, and pharmacokinetics of mexiletine.
    Woosley RL; Wang T; Stone W; Siddoway L; Thompson K; Duff HJ; Cerskus I; Roden D
    Am Heart J; 1984 May; 107(5 Pt 2):1058-65. PubMed ID: 6326558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral mexiletine in the treatment of refractory ventricular arrhythmias: the role of electrophysiologic techniques.
    Schoenfeld MH; Whitford E; McGovern B; Garan H; Ruskin JN
    Am Heart J; 1984 May; 107(5 Pt 2):1071-8. PubMed ID: 6372423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mexiletine: Antiarrhythmic mechanisms, emerging clinical applications and mortality.
    Olleik F; Kamareddine MH; Spears J; Tse G; Liu T; Yan GX
    Pacing Clin Electrophysiol; 2023 Nov; 46(11):1348-1356. PubMed ID: 37846818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relevance of mexiletine in the era of evolving antiarrhythmic therapy of ventricular arrhythmias.
    Alhourani N; Wolfes J; Könemann H; Ellermann C; Frommeyer G; Güner F; Lange PS; Reinke F; Köbe J; Eckardt L
    Clin Res Cardiol; 2024 Jun; 113(6):791-800. PubMed ID: 38353682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Anti-arrhythmic efficacy of the amiodarone-mexiletine combination in the treatment of resistant complex ventricular arrhythmias].
    Purcaro A; Massacci C; Curzi G; Pigini G; Costantini C; Bilancini A; Blandini A
    G Ital Cardiol; 1986 May; 16(5):417-26. PubMed ID: 3732727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mexiletine-quinidine combination: enhanced antiarrhythmic and electrophysiologic activity in the dog.
    Duff HJ
    J Pharmacol Exp Ther; 1989 May; 249(2):617-22. PubMed ID: 2724143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mexiletine: an effective antiarrhythmic drug for treatment of ventricular arrhythmias in congenital heart disease.
    Moak JP; Smith RT; Garson A
    J Am Coll Cardiol; 1987 Oct; 10(4):824-9. PubMed ID: 3655149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mexiletine: a review of its pharmacological properties and therapeutic efficacy in arrhythmias.
    Chew CY; Collett J; Singh BN
    Drugs; 1979 Mar; 17(3):161-81. PubMed ID: 378646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mexiletine for refractory-ventricular arrhythmias: results using serial electrophysiologic testing.
    DiMarco JP; Garan H; Ruskin JN
    Am J Cardiol; 1981 Jan; 47(1):131-8. PubMed ID: 7457398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indications for mexiletine in the new ESC guidelines and beyond.
    Vamos M; Zsigmond EJ; Hohnloser SH
    Expert Opin Pharmacother; 2023; 24(12):1403-1407. PubMed ID: 37306465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of NS-2, a new class 1 antiarrhythmic agent, and AFD-19, its active metabolite, on ventricular arrhythmias induced by coronary artery occlusion and reperfusion in anesthetized rats: comparison with disopyramide and mexiletine.
    Komori S; Sawanobori T; Tamura K; Kane KA; Parratt JR
    Jpn J Pharmacol; 1994 Jul; 65(3):193-200. PubMed ID: 7799519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination antiarrhythmic treatment among class Ia, Ib, and II agents for ventricular arrhythmias.
    Tanabe T
    Cardiovasc Drugs Ther; 1991 Aug; 5 Suppl 4():827-34. PubMed ID: 1931759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy of mexiletine alone and in combination with class Ia antiarrhythmic drugs for refractory ventricular arrhythmias.
    Whitford EG; McGovern B; Schoenfeld MH; Garan H; Newell JB; McElroy M; Ruskin JN
    Am Heart J; 1988 Feb; 115(2):360-6. PubMed ID: 3341170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mexiletine/quinidine combination therapy: electrophysiologic correlates of anti-arrhythmic efficacy.
    Duff HJ; Mitchell LB; Wyse DG; Gillis AM; Sheldon RS
    Clin Invest Med; 1991 Oct; 14(5):476-83. PubMed ID: 1660369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Impact of late sodium current inhibition on cardiac electrophysiology parameters and ventricular arrhythmias in isolated Langendorff perfused rabbit hearts with short QT interval].
    Huang YW; Chen Y; Wang CY; Wu L
    Zhonghua Xin Xue Guan Bing Za Zhi; 2022 Nov; 50(11):1087-1093. PubMed ID: 36418277
    [No Abstract]   [Full Text] [Related]  

  • 19. Class IB antiarrhythmic drugs: tocainide, mexiletine, and moricizine.
    Snyder DW
    J La State Med Soc; 1989 May; 141(5):21-5. PubMed ID: 2499645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Propafenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias.
    Harron DW; Brogden RN
    Drugs; 1987 Dec; 34(6):617-47. PubMed ID: 3322781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.